EPIX (ESSA Pharma) Accounts Receivable : $0.15 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. ESSA Pharma's accounts receivables for the quarter that ended in Dec. 2024 was $0.15 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. ESSA Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $2.63.

ESSA Pharma Accounts Receivable Historical Data

The historical data trend for ESSA Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Accounts Receivable Chart

ESSA Pharma Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Accounts Receivable

Get a 7-Day Free Trial

0.31

0.49

0.01

0.14

0.16

ESSA Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Receivable	Get a 7-Day Free Trial															0.18	0.22	0.18	0.16	0.15

ESSA Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

ESSA Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

ESSA Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.154	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), ESSA Pharma's accounts receivable are only considered to be worth 75% of book value:

ESSA Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(120.451	+	0.75 * 0.154	+	0.5 * 0	-	3.867
-	0	-	0)	/	44.389
=	2.63

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

ESSA Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ESSA Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.essapharma.com

ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.

Executives

Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Peter Virsik	officer: Chief Operating Officer	131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson	director, officer: Chief Executive Officer	C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood	officer: Chief Financial Officer	3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104